• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New drugs: Exenatide – an injectable diabetic agent and Denosumab – a monoclonal antibody for postmenopausal osteoporosis
Exanatide (Byetta): the first injectable synthetic analogue of the incretin hormone glucagon-like peptide-1 (GLP-1) note that the glyptins inhibit incretin breakdown and are thus incretin “enhancers” not “mimics” PBS approved for type 2 diabetics as an addition to the combination of metformin and  sulphonylurea to help lower HbA1c below 7% or as dual Rx for those who cannot tolerate metformin or a sulphonylurea. dose: is given bd s/c within 1 hour BEFORE meals starting at 5 mcg per dose which should be at least 6 hours apart after 1 month, dose can be increased to 10mcg bd main adverse effect...
Source: Oz E Medicine - emergency medicine in Australia - December 11, 2010 Category: Emergency Medicine Authors: Gary Tags: new drugs Source Type: blogs